‘Globesity’ is a descriptive term for the obesity epidemic now facing the U.S. and indeed, the world. Hyperphagia (i.e. overeating) can lead to metabolic syndrome which in turn can lead to Type 2 diabetes mellitus, heart disease, stroke and some cancers. The World Health Organization even states that more people die each year from the consequences of obesity than from hunger. Something must be done to stem the tsunami of obesity and its resultant medical complications. Our work and that of others suggests that new obesity treatments and anti-obesity medications should be based on those already successful in treating other addictions. This paper looks at empirical evidence linking addictions to food and to drugs such as tobacco, alcohol, cannabis, amphetamines, and cocaine. Hypotheses are put forth as to why hyperphagia is so difficult to treat. Additionally, prenatal programming for addiction is explored. Lessons from successful drug treatment are elucidated and potential pharmaceutical targets for hyperphagia and obesity are suggested.
Keywords: Hyperphagia, metabolic syndrome, Type 2 diabetes mellitus, withdrawal, dopamine, reward pathways, Globesity, pandemic, anorexia, hyperlipidemia, orexin, leptin, deprivation, Dexfenfluramine, fluoxetine, phenylpropanolamine, naltrexone, detoxification, neurobiological
Diabetes-Related Neurological Implications and Pharmacogenomics
Current Pharmaceutical Design Natural Approaches in Diabetes Management: A Review of Diet, Exercise, and Natural Products
Current Pharmaceutical Design Beneficial Effects of Corn Silk on Metabolic Syndrome
Current Pharmaceutical Design Is Metabolic Syndrome X a Disorder of the Brain?
Current Nutrition & Food Science Difference in the Influence of the Lipid Profile as a Coronary Risk Factor in Patients with and Without Diabetes Mellitus
Vascular Disease Prevention Attenuation of Diabetes-induced Cardiac and Subcellular Defects by Sulphur-containing Amino Acids
Current Medicinal Chemistry Is there a Role for Sodium Orthovanadate in the Treatment of Diabetes?
Current Diabetes Reviews Therapeutic Nanosystems for Oral Administration of Insulin
Current Pharmaceutical Biotechnology Diabetes and the Impairment of Reproductive Function: Possible Role of Mitochondria and Reactive Oxygen Species
Current Diabetes Reviews Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews The Cardiovascular Effects of Metformin: Further Reasons to Consider An Old Drug as a Cornerstone in the Therapy of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Insulin Resistance in Type 2 Diabetes - Role of the Adipokines
Current Molecular Medicine Non-Invasive Methods of Glucose Measurement: Current Status and Future Perspectives
Current Diabetes Reviews Interaction of Anthocyanins with Drug-metabolizing and Antioxidant Enzymes
Current Medicinal Chemistry Amylin Replacement With Pramlintide as an Adjunct to Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: A Physiological Approach Toward Improved Metabolic Control
Current Pharmaceutical Design Effects of Thiazolidinediones on Coronary Artery Disease: Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Under Re-organization) Update on the Protective Renal Effects of Metformin in Diabetic Nephropathy
Current Medicinal Chemistry The Role Played by Serine Proteases in the Development and Worsening of Vascular Complications in Type 1 Diabetes Mellitus
Current Diabetes Reviews Herbal Drugs for Diabetic Treatment: An Updated Review of Patents
Recent Patents on Anti-Infective Drug Discovery A Simple High Efficiency Intra-Islet Transduction Protocol Using Lentiviral Vectors
Current Gene Therapy